HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Borderline personality disorder — Clinical Guidelines

Overview

Borderline personality disorder (BPD) is characterized by pervasive instability in interpersonal relationships, self-image, and affects, often accompanied by impulsivity and suicidal behavior. While many symptoms may remit over time, a significant subset experiences persistent symptoms affecting mood, psychosocial adjustment, and overall functioning 1.

Diagnosis

Key diagnostic criteria include pervasive instability in relationships, self-image, and affect, impulsivity, and recurrent suicidal behavior or self-harm 1 13.

No specific laboratory tests; diagnosis primarily clinical based on DSM criteria 1 13.

Grading typically involves severity scales and functional impairment assessments 1 13.

Management

First-line treatment: Dialectical Behavior Therapy (DBT) and other psychotherapies aimed at skill-building and emotional regulation 2 5.

Adjunctive treatments: Psychopharmacology used cautiously, often involving mood stabilizers, antipsychotics, and antidepressants, though no specific medications are FDA-approved for BPD 3 5 6 9.

Polypharmacy caution: Skills training in DBT has been shown to reduce polypharmacy 2.

Comorbidity considerations: Medication choices may be influenced by comorbid conditions and illness severity 3 6.

Special Populations

Pregnancy: Limited specific guidance; management should focus on minimizing risks and supporting mental health 7.

Elderly: No specific studies noted; treatment should adapt to age-related comorbidities and functional status 7.

Comorbidities: Treatment often involves addressing comorbid psychiatric conditions, influencing pharmacological choices 3 6.

Key Recommendations

Prioritize psychotherapy, particularly DBT, as the cornerstone of treatment for BPD (Evidence: Strong 2 5).

Use psychopharmacology cautiously, reserving it for adjunctive support and focusing on minimizing polypharmacy to reduce adverse effects (Evidence: Moderate 2 3 5 6).

Monitor long-term outcomes, recognizing that a subset of patients may experience persistent symptoms requiring ongoing tailored interventions (Evidence: Moderate 1).

References

1 Casellas-Pujol E, Soler J, Schmidt C, Soriano J, Pascual JC. Long-lasting symptoms in borderline personality disorder: Defining an emergent population with differential clinical and therapeutic features. Personality and mental health 2024. link 2 Soler J, Casellas-Pujol E, Fernández-Felipe I, Martín-Blanco A, Almenta D, Pascual JC. "Skills for pills": The dialectical-behavioural therapy skills training reduces polypharmacy in borderline personality disorder. Acta psychiatrica Scandinavica 2022. link 3 Magni LR, Ferrari C, Barlati S, Ridolfi ME, Prunetti E, Vanni G et al.. Psychopharmacological treatment in borderline personality disorder: A pilot observational study in a real-world setting. Psychiatry research 2021. link 4 Terpstra TL, Williamson S. Palliative Care for Terminally Ill Individuals With Borderline Personality Disorder. Journal of psychosocial nursing and mental health services 2019. link 5 Limandri BJ. Psychopharmacology for Borderline Personality Disorder. Journal of psychosocial nursing and mental health services 2018. link 6 Bridler R, Häberle A, Müller ST, Cattapan K, Grohmann R, Toto S et al.. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2015. link 7 Ricke AK, Lee MJ, Chambers JE. The difficult patient: borderline personality disorder in the obstetrical and gynecological patient. Obstetrical & gynecological survey 2012. link 8 Silk KR. The process of managing medications in patients with borderline personality disorder. Journal of psychiatric practice 2011. link 9 Haw C, Stubbs J. Medication for borderline personality disorder: a survey at a secure hospital. International journal of psychiatry in clinical practice 2011. link 10 Pascual JC, Martín-Blanco A, Soler J, Ferrer A, Tiana T, Alvarez E et al.. A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. International clinical psychopharmacology 2010. link 11 Zanarini MC, Frankenburg FR, Khera GS, Bleichmar J. Treatment histories of borderline inpatients. Comprehensive psychiatry 2001. link 12 Snyder S. Pseudologia fantastica in the borderline patient. The American journal of psychiatry 1986. link 13 Kretsch R, Goren Y, Wasserman A. Emotional and cognitive factors in the borderline profile. American journal of psychotherapy 1984. link 14 Frank H, Paris J. Recollections of family experience in borderline patients. Archives of general psychiatry 1981. link 15 Watterson DJ, Collinson S. Copsychotherapy of the individual patient: indications and operative factors. American journal of psychotherapy 1976. link

Borderline personality disorder